XBIT / XBiotech Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 XBIOTECH INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37347 XBIOTECH INC. (Exact name of registrant as specified in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from       to       Commission file number: 001

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Em

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ Transaction Report pursuant to Sect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ Transaction Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its ch

XBiotech Inc. Clawback Policy

Exhibit 97 XBIOTECH INC. CLAWBACK POLICY Definitions For purposes of this Policy, the following definitions shall apply: ● “Accounting Restatement” means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statem

XBiotech Inc. Insider Trading Policy

Exhibit 10.19 XBIOTECH INC. INSIDER TRADING POLICY I. PURPOSE XBiotech Inc. and its subsidiaries (the “Company”) has adopted this Insider Trading Policy (this “Policy”) to help its directors, officers and employees comply with insider trading laws and to prevent even the appearance of improper insider trading. II. SCOPE A. This Policy applies to all directors, officers and employees of the Company

Description of Registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common shares, no par value, of XBiotech Inc. (the “Company,” “we,” “our,” “us,” and “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The followin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37347 XBIOTECH INC. (Exact name of registrant as specified in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from       to       Commission file number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from       to       Commission file number: 001

XBiotech Inc. Clawback Policy

EXHIBIT 97 XBIOTECH INC. CLAWBACK POLICY Definitions For purposes of this policy, the following definitions shall apply: ● “Accounting Restatement” means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ Transaction Report pursuant to Sect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ Transaction Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its ch

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Germany GmbH Germany

XBIT / XBiotech Inc. / SIMARD JOHN - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc. / MCKENZIE W THORPE - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc. / GUT THOMAS - SC 13G/A Passive Investment

SC 13G/A 1 sc13ga020724.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

EXHIBIT 99.1 XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) - XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 XBIOTECH INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. E

Convertible Loan Agreement

EdgarFiling Exhibit 4.1 Execution Version CONVERTIBLE LOAN AGREEMENT This CONVERTIBLE LOAN AGREEMENT (“Agreement”) is made as of January 3, 2024 (the “Effective Date”) by and among XBiotech Inc., a British Columbia corporation (the “Company”), and John Simard (“Lender”). RECITAL Whereas, to provide the Company with additional resources to finance the construction of a new research and development

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) XBIOTECH INC. (Name of Subject Company (Issuer)) XB

SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) XBIOTECH INC. (Name of Subject Company (Issuer)) XBIOTECH INC. (Name of Filing Person (Offeror and Issuer)) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables SC TO-I (Form Type) XBIOTECH INC.

Letter of Transmittal.

EX-99.(a)(1)(ii) Exhibit (a)(1)(ii) Tax ID Certification on file: TOTAL SHARES: 12345678901234 ACCOUNT CODE: 12345678901234 CONTROL CODE: 12345678901234 TO PARTICIPATE IN THE XBIOTECH INC. ISSUER TENDER OFFER YOU MUST SUBMIT YOUR INSTRUCTIONS IN ONE OF THE FOLLOWING WAYS: Option 1) Internet—Visit the Offer Website at tech.computersharecas.com and using the Account Code and Control Code printed abo

Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

EX-99.(a)(1)(iv) Exhibit (a)(1)(iv) Offer to Purchase for Cash by XBiotech Inc. Up to $80,000,000 in Value of Common Shares At a Cash Purchase Price Not Greater than $4.00 per Share Nor Less than $3.80 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON JUNE 15, 2023, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “

Offer to Purchase, dated May 17, 2023.

EX-99.(a)(1)(i) Table of Contents Exhibit (a)(1)(i) Offer to Purchase by XBiotech Inc. Up to $80,000,000 in Value of its Common Shares At a Cash Purchase Price Not Greater Than $4.00 per Share Nor Less Than $3.80 Per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., EASTERN TIME, ON JUNE 15, 2023, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTE

Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

EX-99.(a)(1)(iii) Exhibit (a)(1)(iii) Offer to Purchase for Cash by XBiotech Inc. Up to $80,000,000 in Value of Common Shares At a Cash Purchase Price Not Greater than $4.00 per Share Nor Less than $3.80 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M, EASTERN TIME, ON JUNE 15, 2023, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE

Summary Advertisement, dated May 17, 2023.

EX-99.(a)(5)(ii) Exhibit (a)(5)(ii) This announcement is neither an offer to purchase nor a solicitation of an offer to sell common shares of XBiotech Inc. The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated May 17, 2023, the related Letter of Transmittal and the Offer Website (as defined below) , and any amendments or supplements thereto. The Offer is not being ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer)) XBIOTECH INC. (Name

SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer)) XBIOTECH INC. (Name of Filing Person (Offeror and Issuer)) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number of Class of Securiti

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables SC TO-I (Form Type) XBIOTECH INC. (Exact name of registrant as specified in its charter) Table 1 – Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $80,000,000(1) 0.0001102 $8,816.00 Fees Previously Paid — — Total Transaction Valuation $80,000,000(2) Total Fees Due for Filing $8,816.00 Total Fees Previously Paid

Press Release, dated May 17, 2023.

EX-99.(a)(5)(i) Exhibit (a)(5)(i) XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) – Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Board Member Agreement, dated as of February 27, 2018, by and between XBiotech Inc. and Jan-Paul Waldin.

Exhibit 10.13

Board Member Agreement, dated as of March 20, 2018, by and between XBiotech Inc. and Donald H. MacAdam.

Exhibit 10.14

Form of Nonqualified Share Option Agreement under the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the Annual Report on Form 10-K filed with the SEC on March 15, 2023)

Exhibit 10.10 XBiotech Inc. 2015 Equity Incentive Plan Nonqualified Share Option Agreement This Nonqualified Share Option Agreement (“Agreement”) is made and entered into, subject to shareholder approval, by and between XBiotech Inc. (the “Company”) and ###PARTICIPANTNAME### (“Participant”) to reflect the terms of an option granted to Participant under the XBiotech Inc. 2015 Equity Incentive Plan

Form of Incentive Share Option Agreement under the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Annual Report on Form 10-K filed with the SEC on March 15, 2023)

Exhibit 10.9 XBiotech Inc. 2015 Equity Incentive Plan Incentive Share Option Agreement This Incentive Share Option Agreement (“Agreement”) is made and entered into, subject to shareholder approval, by and between XBiotech Inc. (the “Company”) and ###PARTICIPANTNAME### (“Participant”) to reflect the terms of an option granted to Participant under the XBiotech Inc. 2015 Equity Incentive Plan (“Plan”

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common shares, no par value, of XBiotech Inc. (the “Company,” “we,” “our,” “us,” and “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The followin

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Germany GmbH Germany

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended Decemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ Transaction Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its ch

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBIT / XBiotech Inc / SIMARD JOHN - FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc / MCKENZIE W THORPE - FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc / GUT THOMAS - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc / Lombard International Assurance S.a. - SC 13G Passive Investment

SC 13G 1 tm233258d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBiotech Inc. (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 98400H102 (CUSIP Number) 19 May 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

XBIT / XBiotech Inc / GUT THOMAS - SC 13G Passive Investment

SC 13G 1 sc13g052722.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Letter from Ernst & Young LLP to the Securities and Exchange Commission dated May 13, 2022.

Exhibit 16.1 May 13, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated May 13, 2022, of Xbiotech, Inc. and are in agreement with the statements contained in the last sentence of paragraph 1 and in paragraphs 2 and 3 on page 2 therein. We have no basis to agree or disagree with other statements of the regis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ Transaction Report pursuant to Sect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? Transaction Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its ch

Description of Registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934(incorporated by reference to Exhibit 4.1 to the Annual Report on Form 10-K filed with the SEC on March 15, 2022)

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common shares, no par value, of XBiotech Inc. (the ?Company,? ?we,? ?our,? ?us,? and ?our?), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The followin

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Germany GmbH Germany

XBIT / XBiotech Inc / SIMARD JOHN - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc / MCKENZIE W THORPE - SC 13G Passive Investment

SC 13G 1 sc13g021522.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

XBiotech Inks Clinical Manufacturing Deal XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson

EXHIBIT 99.1 XBiotech Inks Clinical Manufacturing Deal XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson AUSTIN, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) announced today that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture cl

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 XBIOTECH INC. (Exact name of registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBIT / XBiotech Inc / Lombard International Assurance S.a. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBiotech Inc. (Name of Issuer) Common stock, no par value per share (Title of Class of Securities) 98400H102 (CUSIP Number) 15 July 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 XBIOTECH INC. (Exact name of registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Empl

XBiotech Announces Dividend to Holders of Common Stock

EXHIBIT 99.1 XBiotech Announces Dividend to Holders of Common Stock AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) - XBiotech Inc.?s (NASDAQ: XBIT) (?XBiotech?) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stock

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Description of Registrant's securities registered pursuant to Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common shares, no par value, of XBiotech Inc. (the ?Company,? ?we,? ?our,? ?us,? and ?our?), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The followin

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Switzerland AG Switzerland XBiotech Japan K.K. Japan XBiotech Germany GmbH Germany

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? Transaction Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its ch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) (CUSIP Number)

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 23, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

- FORM S-8

As filed with the Securities and Exchange Commission on October 2, 2020 Registration No.

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2020 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Second Amendment to the XBiotech Inc. 2015 Equity Incentive Plan (incorporated by reference to Annex A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 28, 2020)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Switzerland AG Switzerland XBiotech Japan K.K. Japan XBiotech Germany GmbH Germany

Description of Registrant's securities registered pursuant to Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common shares, no par value, of XBiotech Inc. (the “Company,” “we,” “our,” “us,” and “our”), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The followin

Clinical Manufacturing Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on July 16, 2019)

Exhibit 10.14 CLINICAL MANUFACTURING AGREEMENT BY AND BETWEEN [[5252615]] XBIOTECH USA, INC. AN D JANSSEN RESEARCH & DEVELOPMENT LLC 1 [[5252615]] TABLE OF CONTENTS P age Article 1 DEFINITIONS .........................................................................................................1 Article 2 CLINICAL PRODUCT MANUFACTURE AND SUPPLY......................................5 2.1 Manufac

XBIT / XBiotech Inc. 10-K - Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorporation or organizat

Transition Services Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on July 16, 2019)

Exhibit 10.15 [[5258968]] TRANSITION SERVICES AGREEMENT BY AND BETWEEN JANSSEN RESEARCH & DEVELOPMENT, LLC AND XBIOTECH USA, INC. DATED AS OF DECEMBER 30, 2019 [[5258968]] ARTICLE I DEFINITIONS...................................................................................... 1 Section 1.1. D efinitions .............................................................................. 1 Section 1.2

Press Release, dated February 19, 2020.

EXHIBIT 99.(A)(5)(V) XBiotech Announces Final Results of Tender Offer AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the final count by American Stock Transfer & Trust Co., LLC, the depositary for t

XBIT / XBiotech Inc. SC TO-I/A - - SC TO-I/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 4) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number of Class of Securities) John Simard Presid

XBIT / XBiotech Inc. / MCKENZIE W THORPE - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBIT / XBiotech Inc. / SIMARD JOHN - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBIT / XBiotech Inc. / BAY STREET FINANCIAL S.A. - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. –)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) February 03, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

XBIT / XBiotech Inc. / GUT THOMAS - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) February 3, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Press Release, dated February 13, 2020.

Exhibit (a)(5)(iii) XBiotech Announces Preliminary Results of Tender Offer AUSTIN, Texas, Feb.

XBIT / XBiotech Inc. / RENNES FONDATION - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) February 03, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

XBIT / XBiotech Inc. SC TO-I/A - - SC TO-I/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number of Class of Securities) John Simard Presid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer) and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number of Class of Securities) John Simard Presid

Press Release (corrected), dated February 13, 2020

EXHIBIT 99.(A)(6)(IV) Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) - This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor. The corrected press release reads: XBiotech Announces Preliminary Results of Tender Offer XBiotech Inc. (NASDAQ: XBI

XBIT / XBiotech Inc. SC TO-I/A - - SC TO-I/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number of Class of Securities) John Simard Presid

XBIT / XBiotech Inc. / RENNES FONDATION - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Offer to Purchase XBiotech Inc. Up to $420,000,000 in Value of its Common Shares At a Cash Purchase Price Not Greater Than $33.00 per Share Nor Less Than $30.00 Per Share

ex-a1i XBiotech Inc. SC TO-I Exhibit (a)(1)(i) Offer to Purchase by XBiotech Inc. Up to $420,000,000 in Value of its Common Shares At a Cash Purchase Price Not Greater Than $33.00 per Share Nor Less Than $30.00 Per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON FEBRUARY 12, 2020, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY

XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares

ex-a5i XBiotech Inc. SC TO-I Exhibit (a)(5)(i) XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares AUSTIN, Texas, January 14, 2020 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are properly t

Notice of Guaranteed Delivery For Tender of Common Shares of XBiotech Inc.

EX-99.(A)(1)(III) 4 ex99-a1iii.htm NOTICE OF GUARANTEED DELIVERY ex-a1iii 1 XBiotech Inc. SC TO-I Exhibit (a)(1)(iii) Notice of Guaranteed Delivery For Tender of Common Shares of XBiotech Inc. THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON FEBRUARY 12, 2020, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATIO

Offer to Purchase for Cash XBiotech Inc. Up to $420,000,000 in Value of Common Shares At a Cash Purchase Price Not Greater than $33.00 per Share Nor Less than $30.00 per Share

ex-a1iv XBiotech Inc. SC TO-I Exhibit (a)(1)(iv) Offer to Purchase for Cash by XBiotech Inc. Up to $420,000,000 in Value of Common Shares At a Cash Purchase Price Not Greater than $33.00 per Share Nor Less than $30.00 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M, NEW YORK CITY TIME, ON FEBRUARY 12, 2020, UNLESS THE OFFER IS EXTENDED (SUCH DATE AND TIME, AS TH

Offer to Purchase for Cash XBiotech Inc. Up to $420,000,000 in Value of Common Shares At a Cash Purchase Price Not Greater than $33.00 per Share Nor Less than $30.00 per Share

EX-99.(A)(1)(V) 6 ex99-a1v.htm LETTER TO CLIENTS FOR USE BY BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES ex-a1v XBiotech Inc. SC TO-I Exhibit (a)(1)(v) Offer to Purchase for Cash by XBiotech Inc. Up to $420,000,000 in Value of Common Shares At a Cash Purchase Price Not Greater than $33.00 per Share Nor Less than $30.00 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL

XBiotech Inc. SC TO-I

xb-to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number of Class of Securities) John Simard President and Chie

This announcement is neither an offer to purchase nor a solicitation of an offer to sell common shares of XBiotech Inc.. The Offer (as defined below) is made solely by the Offer to Purchase, dated January 14, 2020, and the related Letter of Transmitt

ex-a5ii XBiotech Inc. SC TO-I Exhibit (a)(5)(ii) This announcement is neither an offer to purchase nor a solicitation of an offer to sell common shares of XBiotech Inc.. The Offer (as defined below) is made solely by the Offer to Purchase, dated January 14, 2020, and the related Letter of Transmittal, and any amendments or supplements thereto. The Offer is not being made to, nor will tenders be ac

Letter of Transmittal For Tender of Common Shares of XBiotech Inc. At a Purchase Price Not Greater than $33.00 per Share Nor Less than $30.00 per Share Pursuant to the Offer to Purchase Dated January 14, 2020

ex-a1ii 1 XBiotech Inc. SC TO-I Exhibit (a)(1)(ii) Letter of Transmittal For Tender of Common Shares of XBiotech Inc. At a Purchase Price Not Greater than $33.00 per Share Nor Less than $30.00 per Share Pursuant to the Offer to Purchase Dated January 14, 2020 THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON FEBRUARY 12, 2020, UNLESS THE OFFER IS EX

XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline

EX-99.1 6 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline AUSTIN, Texas, Dec. 30, 2019 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) announced today closing of the sale of the Company’s True Human antibody Bermekimab to Janss

Clinical Manufacturing Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc.

EX-10.2 4 exh102.htm EXHIBIT 10.2 EXHIBIT 2.4(b)(iv) [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. CLINICAL MANUFACTURING agreement By and between XBiotech USA, Inc. And JANSSEN RESEARCH & DEVELOPMENT LLC TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Art

Asset Purchase Agreement, dated as of December 7, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on December 30, 2019)

EXHIBIT 2.1 EXECUTION VERSION [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Asset Purchase Agreement Dated as of December 7, 2019 between JANSSEN BIOTECH, INC. and XBIOTECH INC. TABLE OF CONTENTS Page ARTICLE I Definitions; Interpretation Section 1.1. Def

Transition Services Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc.

EX-10.3 5 exh103.htm EXHIBIT 10.3 EXHIBIT 2.4(b)(vi) [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. TRANSITION SERVICES AGREEMENT BY AND BETWEEN JANSSEN RESEARCH & DEVELOPMENT, LLC AND XBIOTECH USA, INC. DATED AS OF DECEMBER 30, 2019 ARTICLE I DEFINITIONS

IP Non-Assertion and License Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on December 30, 2019)

Exhibit 2.4(b)(vii) [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Dated December 30, 2019 JANSSEN BIOTECH, INC. - and - XBIOTECH INC. IP NON-ASSERTION AND LICENSE AGREEMENT CONTENTS PAGE 1. INTERPRETATION 4 2. NON-ASSERTION AND GRANT OF LICENSES 10 3. SUB

XBiotech Inc. Consolidated Statement of Operations (in thousands, except share and per share data)

EX-99.2 7 exh992.htm EXHIBIT 99.2 Exhibit 99.2 XBiotech Inc. Consolidated Statement of Operations (in thousands, except share and per share data) Nine Months Ended September 30, 2019 As Reported Adjustments Pro Forma Gross Revenues: Bermekimab IP revenue $ – $ 674,566 $ 674,566 Clinical trial drug manufacture revenue – 13,500 13,500 Clinical trial service revenue – 33,821 33,821 Total gross revenu

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) - XBiotech Inc. (NAS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 7, 2019 XBIOTECH INC. (Exact Name of Registrant as Specified in Charter) British Columbia Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (IRS Employer

XBIT / XBiotech Inc. 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

XBIT / XBiotech Inc. 10-Q - Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Board Member Agreement, dated as of July 10, 2019, by and between XBiotech Inc. and Peter Libby (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on July 16, 2019)

Exhibit 10.1 Board Member Agreement This Agreement (this “Agreement”), dated as of the 10 day of July, 2019, is between Peter Libby, M.D., an individual having a residence at 109 Larch Road Cambridge MA 02138 (the “Board Director”), and XBiotech Inc., a British Columbia corporation with its principal executive office located at 5217 Winnebago Lane, Austin, Texas 78744 (the “Company”). WHEREAS, the

XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board

EXHIBIT 99.1 XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board AUSTIN, Texas, July 10, 2019 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) announced today that Peter Libby, M.D., has been appointed to the Company’s Corporate Board of Directors. Dr. Libby has played a pioneering role in discovering how infla

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2019 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2019 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

XBIT / XBiotech Inc. / RENNES FONDATION - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) June 4, 2019 (Date of Eve

XBiotech Announces Pricing of Public Offering of Common Shares

EXHIBIT 99.1 XBiotech Announces Pricing of Public Offering of Common Shares AUSTIN, Texas, May 31, 2019 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) today announced the pricing of an underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share. The offering is expected to close on or about June 4, 2019, subject to the satisfaction of customary clo

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 31, 2019 XBIOTECH INC. (Exact Name of Registrant as Specified in Charter) British Columbia Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (IRS Employer Ide

Purchase Agreement, dated May 31, 2019, between XBiotech Inc. and Piper Jaffray & Co.

Exhibit 1.1 Execution Copy 4,848,485 Shares1 XBiotech Inc. Common Stock PURCHASE AGREEMENT May 31, 2019 PIPER JAFFRAY & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: XBiotech Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), proposes to sell to Piper Jaffray & Co. (the “Underwriter”) an aggregate of 4,848

XBiotech Inc. 4,848,485 Common Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-213218 PROSPECTUS SUPPLEMENT (To Prospectus dated September 1, 2016) XBiotech Inc. 4,848,485 Common Shares We are offering 4,848,485 common shares in this offering. Our common shares are listed on the NASDAQ Global Select Market under the symbol “XBIT.” On May 30, 2019, the last reported sale price for our common shares on the NASDAQ Global Sel

XBIT / XBiotech Inc. S-3MEF - - FORM S-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 XBIOTECH INC. (Exact name of registrant as specified in its charter) British Columbia, Canada Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 5217 Winnebago Lane Austin, TX 78744 (512) 386-2900

(Subject to Completion, Dated May 30, 2019)

Filed Pursuant to Rule 424(b)(5) Registration No. 333-213218 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities has become effective under the Securities Act of 1933. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell these securities and are not soliciting an o

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 30, 2019 XBIOTECH INC. (Exact Name of Registrant as Specified in Charter) British Columbia Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (IRS Employer Ide

XBiotech Announces Public Offering of Common Shares

EXHIBIT 99.1 XBiotech Announces Public Offering of Common Shares AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions. XBiotech intends to grant the underwriter in the offering a 30-day option to purchase additional common shares. Piper Jaffray is ac

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2019 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Empl

XBIT / XBiotech Inc. 10-Q Quarterly Report FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Equity Distribution Agreement, dated April 30, 2019, between XBiotech Inc. and Piper Jaffray & Co.

Exhibit 10.1 Execution Copy XBiotech Inc. EQUITY DISTRIBUTION AGREEMENT April 30, 2019 PIPER JAFFRAY & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), XBiotech Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), proposes to issue and sell from time to

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2019 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Em

XBiotech Inc. Up to 4,334,453 Shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-213218 PROSPECTUS SUPPLEMENT (To Prospectus dated September 1, 2016) XBiotech Inc. Up to 4,334,453 Shares Common Stock We have entered into an equity distribution agreement with Piper Jaffray & Co., or Piper Jaffray, relating to shares of our common stock, no par value, offered by this prospectus supplement and the accompanying prospectus. Unde

XBIT / XBiotech Inc. DEF 14A DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2019 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Em

XBIT / XBiotech Inc. FORM 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 to Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdictio

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Switzerland AG Switzerland XBiotech Japan K.K. Japan XBiotech Germany GmbH Germany

XBIT / XBiotech Inc. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorporation or organizat

XBIT / XBiotech Inc. / SIMARD JOHN - FORM SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBIT / XBiotech Inc. / RENNES FONDATION - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 21, 2018 (Date o

XBIT / XBiotech Inc. / MCKENZIE W THORPE - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBIT / XBiotech Inc. / RENNES FONDATION - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2018 (Date o

XBIT / XBiotech Inc. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

XBiotech Announces Dismissal of Securities Class Action Suit

EXHIBIT 99.1 XBiotech Announces Dismissal of Securities Class Action Suit AUSTIN, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ: XBIT) announced today that the honorable Judge Dustin M. Howell of the 459th Travis County District Court has issued a letter ruling granting the Company’s Motion to Dismiss the securities class action complaint brought against XBiotech (Case D-1-GN-17-00

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 24, 2018 XBIOTECH INC. (Exact Name of Registrant as Specified in Charter) British Columbia Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (IRS Employer

XBIT / XBiotech Inc. FORM 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorporation or organiz

XBIT / XBiotech Inc. FORM 10-Q/A (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified

XBIT / XBiotech Inc. CORRESP

September 4, 2018 United States Securities and Exchange Commission Division of Corporation Finance Washington, D.

XBIT / XBiotech Inc. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

XBIT / XBiotech Inc. FORM 10-Q/A (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified

XBIT / XBiotech Inc. CORRESP

8201 E Riverside Dr. Bldg. 4, Ste. 100 — Austin, TX 78744 — Phone: (512) 386-2900 — Fax: (512) 386-5505 Web: www.xbiotech.com August 1, 2018 United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: XBiotech Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 File No. 001-37347 To Whom It May Concern: Pursuant to a letter receveid from the S

XBIT / XBiotech Inc. FORM 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorp

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2018 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

XBIT / XBiotech Inc. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

XBIT / XBiotech Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

XBIT / XBiotech Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2018 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2018 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Em

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2018 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Em

XBIT / XBiotech Inc. FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorporation or organizat

List of subsidiaries

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Switzerland AG Switzerland XBiotech Japan K.K. Japan XBiotech Germany GmbH Germany

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBIT / XBiotech Inc. / GUT THOMAS - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBIT / XBiotech Inc. / MCKENZIE W THORPE - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBIT / XBiotech Inc. / SIMARD JOHN - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2018 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2018 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. E

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2017 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBIT / XBiotech Inc. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2017 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S

XBIT / XBiotech Inc. FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2017 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

XBiotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 9, 2017 XBIOTECH INC. (Exact Name of Registrant as Specified in Charter) British Columbia Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (IRS Employer Ide

XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis

EdgarFiling EXHIBIT 99.1 XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis AUSTIN, Texas, June 09, 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) announced today that an Independent Data Monitoring Committee (IDMC) has performed its second prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company?s novel can

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2017 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Empl

XBiotech FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

XBiotech DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

XBiotech DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

XBiotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 28, 2017 XBIOTECH INC. (Exact Name of Registrant as Specified in Charter) British Columbia Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (IRS Employer I

XBiotech to Provide First Quarter 2017 Business Update

EdgarFiling Exhibit 99.1 XBiotech to Provide First Quarter 2017 Business Update AUSTIN, Texas, April 28, 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) announced today it will host a conference call and live audio webcast on Thursday, May 4, 2017, at 8:30 a.m. Eastern Time, to provide an overview of its corporate and clinical activities. The call will encompass developments during the first q

EX-99.2

EXHIBIT 99.2

XBiotech Announces Outcome of EMA’s Oral Explanation Meeting

EdgarFiling EXHIBIT 99.1 XBiotech Announces Outcome of EMA?s Oral Explanation Meeting AUSTIN, Texas, April 20, 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) announced today that the European Medicines Agency (EMA) rendered a negative ?trend? vote after meeting with the Company to discuss the ?Day 180 List of Outstanding Issues? related to the Company?s marketing authorization application (MA

XBiotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2017 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Em

XBiotech SC 13G/A (Passive Acquisition of More Than 5% of Shares)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) March 15, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

XBiotech SC 13G/A (Passive Acquisition of More Than 5% of Shares)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) March 15, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

EX-21.1

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Switzerland AG Switzerland XBiotech Japan K.K. Japan XBiotech Germany GmbH Germany

XBiotech FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorporation or organizat

Subscription agreements with accredited investors (the “Subscription Agreements”) providing for the issuance and sale by the Company of approximately $31 million of common shares in a registered direct offering(filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on March 03, 2017 (File No. 001-37347) and incorporated herein by reference)

Exhibit 10.1 SUBSCRIPTION AGREEMENT This subscription agreement (this ?Subscription Agreement?) is made as of March , 2017, by and between the investor identified on the signature pages hereto (?Investor?) and XBiotech, Inc., a British Columbia corporation (the ?Company?), and the parties hereto agree as follows: 1. Subscription (a) The Company has authorized the sale and issuance to the Investor

XBiotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2017 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

XBiotech Announces Registered Direct Offering of Common Shares

EX-99.1 4 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 XBiotech Announces Registered Direct Offering of Common Shares AUSTIN, Texas, March 03, 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) today announced that it has entered into definitive agreements to sell an aggregate of approximately US$31,000,000 of common shares in a registered direct offering. The transaction was completed from the Company’s

2,450,000 Shares Common Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-213218 PROSPECTUS SUPPLEMENT (To Prospectus dated September 1, 2016) 2,450,000 Shares Common Shares We are offering 2,450,000 common shares in a registered direct offering at a negotiated price of $13.00 per share directly to accredited investors pursuant to this prospectus supplement and the accompanying prospectus and subscription agreements

XBIT / XBiotech Inc. / MCKENZIE W THORPE - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBIT / XBiotech Inc. / SIMARD JOHN - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

XBiotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2017 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBIT / XBiotech Inc. / RENNES FONDATION - SC 13G/A (AMENDMENT NO.1) Passive Investment

SC 13G/A (AMENDMENT NO.1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December

XBiotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBIT / XBiotech Inc. / RENNES FONDATION - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 XBIOTECH INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) July 5, 2016 (Date of Event

Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 Thispresentationcontainsforward-lookingstatements,includingdeclarationsregarding management'sbeliefsandexpectations,thatinvolvesubstantialrisksandu

Exhibit 99.1 Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 Thispresentationcontainsforward-lookingstatements,includingdeclarationsregarding management'sbeliefsandexpectations,thatinvolvesubstantialrisksanduncertainties. Insomecases,youcanidentifyforward-lookingstatementsbyterminologysuchas "may," "will," "should," "would," "could," "expects,

XBiotech FORM 8-K/A (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S

XBiotech FORM 8-K/A (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S

Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 This presentation contains forward - looking statements, including declarations regarding management's beliefs and expectations,that involve substa

Exhibit 99.1 Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 This presentation contains forward - looking statements, including declarations regarding management's beliefs and expectations,that involve substantial risks and uncertainties . In some cases, you can identify forward - looking statements by terminology such as "may," "will," "shoul

Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 This presentation contains forward - looking statements, including declarations regarding management's beliefs and expectations,that involve substa

Exhibit 99.1 Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 This presentation contains forward - looking statements, including declarations regarding management's beliefs and expectations,that involve substantial risks and uncertainties . In some cases, you can identify forward - looking statements by terminology such as "may," "will," "shoul

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S.

XBiotech FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

XBiotech FORM 8-K (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S

Common Stock Sales Agreement with H.C. Wainwright & Co. LLC which establishes an at-the-market equity program (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 26, 2016 (File No. 001-37347) and incorporated herein by reference)

Exhibit 10.1 Execution Copy XBIOTECH INC. $50,260,000 cOMMON STOCK SALES AGREEMENT September 26, 2016 H.C. Wainwright & Co. LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: XBiotech Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co. LLC (?HCW?), as follows: 1. Issuance and Sale of Placement Shares. Company agrees that, from time to time during th

XBiotech Inc. Up to $50,260,000 of Shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-213218 PROSPECTUS SUPPLEMENT (To Prospectus dated September 1, 2016) XBiotech Inc. Up to $50,260,000 of Shares Common Stock We have entered into a sales agreement with H.C. Wainwright & Co., LLC, or H.C. Wainwright, relating to shares of our common stock, no par value, offered by this prospectus supplement and the accompanying underlying prospe

XBiotech ESP

XBiotech Inc. 8201 E. Riverside Dr. Building 4, Suite 100 Austin, Texas 78744 August 30, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Joseph McCann Re: XBiotech Inc. Registration Statement on Form S-3 Filed August 19, 2016 File No. 333-213218 Dear Mr. McCann: Pursuant to Rule 461 under the Securities Act of 19

XBiotech FORM S-3

As filed with the Securities and Exchange Commission on August 19, 2016 Registration No.

XBiotech FORM S-3

As filed with the Securities and Exchange Commission on August 19, 2016 Registration No.

XBiotech FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emp

Amendment to the XBiotech Inc. 2015 Equity Incentive Plan (incorporated by reference to Annex A to the Company’s Definitive Additional Materials on Schedule 14A filed with the SEC on May 25, 2016).

Supplement to Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

XBiotech to Present Positive Preliminary Survival Data on Xilonix™ at the 18th European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer

EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 XBiotech to Present Positive Preliminary Survival Data on Xilonix™ at the 18th European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer First Time Pivotal Phase III Xilonix Data to be Unveiled at Major Scientific Congress, Including Positive Preliminary Overall Mean Survival Data for Responders Developed Specifically to Treat A

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 24, 2016 XBIOTECH INC. (Exact Name of Registrant as Specified in Charter) British Columbia Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (IRS Employer Ide

XBiotech FORM 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specified in

8201 E Riverside Dr. Bldg. 4, Ste. 100

Exhibit 10.1 8201 E Riverside Dr. Bldg. 4, Ste. 100? Austin, TX 78744? Phone: (512) 386-2900 ? Fax: (512) 386-5505 Web: www.xbiotech.com Scott Whitehurst Re: Offer of Employment Dear Scott, On behalf of XBiotech USA Inc., I am pleased to offer you a position as Chief Financial Officer. In this capacity, you will be paid at a gross semi-monthly rate of $16,666.67. You will report to John Simard, CE

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. Emplo

EX-24

POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints David G.

XBiotech DEFINITIVE ADDITIONAL MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

XBiotech DEFINITIVE PROXY STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

XBiotech FORM 10-K/A (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 to Form 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2015 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as s

XBiotech FORM 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Commission file number 001-37437 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorporation or organizat

EX-21.1

Exhibit 21.1 LIST OF SUBSIDIARIES Name Country XBiotech USA, Inc. United States (Delaware) XBiotech Switzerland AG Switzerland XBiotech Japan K.K. Japan XBiotech Germany GmbH Germany

XBiotech SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc. / MCKENZIE W THORPE - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

XBIT / XBiotech Inc. / Gut Josef Karl Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 XBIOTECH INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 98400H102 (CUSIP No.) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file

XBiotech to Host Overview of Strategy and Findings for its European Phase III Trial for treatment of Colorectal Cancer with Xilonix™

EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 XBiotech to Host Overview of Strategy and Findings for its European Phase III Trial for treatment of Colorectal Cancer with Xilonix™ AUSTIN, TX, January 7, 2016 – XBiotech (NASDAQ: XBIT), the world's leading developer of next-generation True Human™ therapeutic antibodies, announced today it will host a conference call and live audio webcast on Friday,

Phase III Data Summary and Discussion A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy

EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 Phase III Data Summary and Discussion A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy 08 January 2016 Clinical Protocol Synopsis STUDY TITLE: A Double Blind, Placebo Controlled Pivotal Phase III Study Evaluating XILONIX™ in Symptomatic Colorectal C

XBiotech Reports Additional Positive Data from Phase III European Trial of Xilonix™ in Advanced Colorectal Cancer Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET

Exhibit 99.3 XBiotech Reports Additional Positive Data from Phase III European Trial of Xilonix? in Advanced Colorectal Cancer Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET AUSTIN, TX, January 8, 2016 ? XBiotech (NASDAQ: XBIT), developer of True Human? therapeutic antibodies, today announced that it has completed data analysis for its Phase III European study and will

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2016 XBIOTECH INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada (State of Incorporation) 001-37347 (Commission File Number) N/A (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-37437 XBIOTECH INC. (Exact name of registrant as specifie

XBiotech 2005 Incentive Stock Option Plan (Restated) (incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form S-8 filed with the SEC on October 19, 2015)

Exhibit 4.4 XBIOTECH INC. XBIOTECH 2005 INCENTIVE STOCK OPTION PLAN (RESTATED TO REFLECT AMENDMENTS TO DATE) XBIOTECH INC. XBIOTECH 2005 INCENTIVE STOCK OPTION PLAN 1. PURPOSE of the plan 1.1 Purpose of this Plan. The purpose of this Plan is to promote the interests of the Company by: (a) furnishing certain directors, officers, employees or consultants of the Company or an Affiliate or other perso

XBiotech FORM S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 XBIOTECH INC. (Exact name of Registrant as specified in its charter) Canada N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 8201 E. Riverside Dr. Bldg. 4, Ste. 100 Austin, TX 78744 (Address of Principal E